Friday, 10 February 2012

A tad busy on the FxMax project

There have been a few ops come and go, but I have been busy helping a good friend get a new project up and running which has not left much time to dedicate to the screens.

On the macro front things seem to be looking a tad brighter as far as the data goes and everywhere else for that matter unless you happen to be a Greek civil servant or poli... Just goes to show that if you kick the can down the road long enough and throw enough cash at the problem it will go away.... well.. the market might forget about it for a spell.

By the look of it the Nasdaq is leading the pack higher as per normal and is well on its way to test the 161.8 % Fib @ 2576.96.

March ES mini contract - ESH2 currently finding some resistance at the Daily 141.4 % Fib. Ideally, the Daily chart suggests that the upside target for this leg would be in the vicinity of 1368.25 ( AB=CD)  to 1376.50 ( 161.8 % Fib extension after a CD 61.8 retrace) zone.  












March WTI Crude - CLH2, Daily chart has turned bullish with the target set in the 106.70 ( AB=CD) to 107.10 ( 141.4% Fib extension from the 70.7 pullback at 95.43)  zone.
4 Hrly charts are suggesting we require a brief pullback or some consolidation at lower levels before the next assault higher towards target.
Currently we are in the 4 Hrly target zone of the up move at channel resistance and the 78.6% Fib. Whilst there looks to be further  upward  momentum I will be looking for signs on the lower time frames that this move is near an end and a retrace is underway. Confirmation would come on a 4 Hrly break and close under  the 222 ema.


















Spot Gold - XAUUSD, Is caught in a consolidation zone between 1698 and 1760.  On a daily chart current price action does resemble that of the highs put in in Nov and Dec of 2011, although ideal target would be an attempt at previous highs close to 1800 . Daily close under the 11 ema would have me looking for a retracement back to the 50 and 200 day smas.

















No comments: